Exco InTouch announces the commencement of its full mobile phone electronic data capture (EDC) study using the Western Ontario and McMaster Osteoarthritis (WOMAC) NRS 3.1 index after the success of their pilot study.
(9 January, 2009) Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, announces the commencement of its full mobile phone electronic data capture (EDC) study using the Western Ontario and McMaster Osteoarthritis (WOMAC) NRS 3.1 index after the success of their pilot study. The initial study is highlighted in Exco InTouch's technical poster, 'Electronic Data Capture Using WOMAC NRS 3.1 Index: a Pilot Study of Cellular Technology in OA' which is available free-of-charge to download at www.excointouch.com.The preliminary study involved 12 patients and verified the benefits of EDC by asking patients to complete questionnaires via their mobile telephone. The full study is now live and currently enrolling patients, already enlisting 31 subjects. The aim of the study is to further compare the effectiveness of patient self-reported outcome questionnaires completed on paper with those completed via a mobile phone using m-WOMAC, Exco InTouch's electronic version of the WOMAC Index.
The WOMAC index is a validated instrument used for assessing hip and knee Osteoarthritis (OA) and has gone through several validation tests and has
been found to be a reliable and responsive measure of outcome in a variety of clinical environments. The index consists of a self-assessment questionnaire and addresses three dimensions of pain, disability and joint stiffness in OA through 24 questions. The index was modified slightly by Exco InTouch for use as a questionnaire application on mobile phones in the pilot study to evaluate the use of cellular technology in capturing the WOMAC NRS 3.1 index. Each of the patients, ten of whom had concomitant hand OA, completed three EDC questionnaires with a mobile phone using m-WOMAC.
The completion time was automatically recorded and this method was found to be both convenient and efficient. The initial data suggest that the m-WOMAC is comparable to the traditional paper-based version of the questionnaire.
Tim Davis, Co-Founder, Exco InTouch comments: "We were overwhelmed with the success of the preliminary study into EDC using m-WOMAC. With this full study we will examine this electronic method on a broader range of subjects. EDC using a mobile phone offers unique benefits to both the patient and the clinical trial organiser, including simplifying the collection of patient-reported data and improving product-to-market time"
Exco InTouch's m-WOMAC is a Java-based application which runs on a patient's mobile phone and facilitates the completion of EDC questionnaires. Using m-WOMAC, questions are sent directly to a patient's mobile phone via text message. Patients are prompted to respond by entering a unique PIN number which ensures that data integrity is preserved. m-WOMAC from Exco InTouch removes the need for paper-based questionnaires and clinic attendance, facilitating EDC for both patients and clinical trial organisers. The m-WOMAC has been approved by the originator of WOMAC Index, and patients have rated the m-WOMAC self-reporting process as 'easy' or 'moderately easy' including those with limited dexterity.
For further information on the m-WOMAC or for a copy of the poster, please call +44 1279 408 210 or +1 949 725 2946 or visit www.excointouch.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.